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Purpose:  We  quantified  mRNA  expression  of  candidate  genes  for  proliferation  (KIF14  and  E2F3)  in  a  large
retinoblastoma tumor cohort and associated with disease phenotype.
Methods: KIF14 and E2F3 mRNA expression was quantified by real time PCR in 57 retinoblastoma (RB) tumors, 3 RB
cell lines, and control samples that included 4 each fetal, age-matched, adult retinas. Immunohistochemistry was done to
confirm KIF14 and E2F3 protein expression in tumor cells. The mRNA expression levels were correlated with disease
phenotypes including the significance of chemotherapy on tumors.
Results: There was statistically significant overexpression of KIF14 and E2F3 mRNA in tumors compared with control
retinas  (p<0.0001).  Further,  E2F3  also  showed  a  significant  overexpression  compared  to  RB  cell  lines  (p=0.01).
Immunohistochemistry confirmed KIF14 and E2F3 protein overexpression in tumor cells. KIF14 had significant mRNA
overexpression with older age (p=0.01) in presenting patients and in unilateral RB patients (p=0.04). Chemotherapy-
treated tumors showed a significant decrease in KIF14 and E2F3 expression compared to untreated tumors (p<0.01 and
0.001, respectively).
Conclusions: This report confirms significant mRNA overexpression of KIF14 and E2F3 together in a large cohort of
RB tumors. The decreased expression in chemotherapy treated cases needs further validation in a large chemotherapy-
treated cohort.
Recent advancements in retinoblastoma (RB) research
yielded vital information on additional events after two hits in
RB  progression.  1q31–32  (62%)  and  6p22  (43%)  are  the
regions more widely shown to cause gain of site in RB tumors
[1]. Studies have shown the KIF14 gene in the 1q31–32 region
[2] and the E2F3/DEK genes in the 6p22 region [3,4] are the
potential candidate genes that cause the gain of site.
KIF14, a mitotic kinesin gene, has been predicted to be a
possible  oncogene  in  the  1q  region,  and  was  found  to
overexpress by more than 2 orders of magnitude in RB [2].
Further, KIF14 overexpression has a strong correlation with
age at diagnosis in RB, and probably represents the amount
of  chromosomal/genetic  instability  required  for  tumor
formation [5]. The level of KIF14 has been correlated with
mitotic progression in the cell cycle, and this protein, along
with  the  microtubule-bundling  protein  PRC1  and  citron
kinase, with which it interacts, plays an important role in
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cytokinesis  during  midbody  formation  and  completion  of
cytokinesis [6].
E2F,  in  conjunction  with  its  dimerization  partner,
regulates genes that play a role in DNA replication [7,8].
Reports  show  that  tumors  with  complete  gain  at  loci  on
chromosome 6p were diagnosed significantly later with a
median age at diagnosis [3]. Chromosome 6p gain is also
common in bladder cancer and associated with an elevated
risk of progression of bladder cancer [9]. The objective of the
present work was to quantify the mRNA expression of KIF14
in a large cohort of 57 RB tumors, which includes 28 tumor
samples previously reported by us ( [5]; used with publisher’s
permission), along with E2F3, in the same cohort, and do a
phenotype correlation.
METHODS
Clinical samples: The study adhered to the Declaration of
Helsinki. This study was conducted at the Medical Research
Foundation  and  Vision  Research  Foundation,  Sankara
Nethralaya, India, and was approved by the institutional ethics
boards. Informed consent was obtained from the parents of
RB patients for the research use of RB tumor samples obtained
from enucleated eyes removed as a part of treatment. Normal
human retinas were obtained from the C.U. Shah Eye Bank
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235(Medical  Research  Foundation,  Sankara  Nethralaya,
Chennai) and the Lions Eye Bank (The Regional Institute of
Ophthalmology,  Chennai),  after  proper  approval  and  the
eyeballs were examined under the microscope to rule out any
pre-existing pathology. Two fetal retinas were commercially
purchased (Advanced Bioscience Resources, Inc., Alameda,
CA), after proper ethical clearance and 2 were gifted by Rod
Bremner,  (Toronto  Western  Research  Institute,
Toronto,Canada).  In  total,  57  RB  tumor  samples  were
collected from eyes removed as a part of therapy in patients
with age at diagnosis between 1 to 84 months. Out of the 57
samples,  2  samples  were  obtained  from  patients  who
underwent chemotherapy before enucleation. Further, out of
57  samples  studied,  KIF14  mRNA  expression  data  of  28
samples previously published by us [5] were selected for this
study.
RNA extraction and reverse transcription: Total RNA was
extracted  from  tumors  and  normal  healthy  retina  by  the
guanidine  isothiocyanate  and  chloroform  method  (TRI
Reagent®;  Sigma  Aldrich,  Bangalore,  India)  as  per
manufacturer’s instructions. All RNA samples were treated
with Turbo DNase® (Ambion, Genetix Biotech Asia Pvt. Ltd,
Chennai, India). For all samples, 1 μg total RNA was used to
synthesize first-strand cDNA using SuperScript II® reverse
transcriptase (Invitrogen, Joyvel, Chennai, India) and random
primers.
Real-time RT–PCR analyses: TaqMan gene expression assays
were  used  to  quantify  the  mRNA  expression  of  KIF14
(Hs00978216_m1) and E2F3 (Hs00605457_m1) normalized
against  two  endogenous  controls:  GAPDH
(Hs99999905_m1)  and  HPRT  (Hs99999909_m1;  Applied
Biosystems,  LabIndia,  Chennai,  India).  Quantification  of
gene expression was performed in triplicate in a 20 μl volume
in 96 well plates on an ABI prism 7300 real time PCR System.
Each reaction included 1X TaqMan primer probe mix, 1X
TaqMan  Universal  PCR  Master  Mix,  and  100  ng  cDNA.
Cycling conditions were as follows: 2 min at 50 °C, 10 min at
95 °C, and 40 cycles of 15 s at 95 °C plus 1 min at 60 °C. The
normalized  gene-of-interest  (GOI)  expression  levels  were
calculated as follows: Ct values were transformed to quantities
by using the comparative Ct method. Here, the calibrator’s
(F2) quantities for each gene were set to 1. The normalization
factor for each sample was calculated by taking the geometric
mean of the two housekeeping genes (GAPDH and HPRT)
using  geNorm  software.  The  normalized  GOI  expression
levels were calculated by dividing the raw GOI quantities for
each sample by the appropriate normalization factor.
Immunohistochemistry: Paraffin sections of RB tumors and
non-neoplastic  retina  from  a  52-year-old  donor’s  eyeball
(5 µm thick) were dewaxed and rehydrated. Antigen retrieval
was  performed  to  unmask  the  antigens  for  better  antigen
antibody  interactions.  Following  the  dewaxing  and
rehydration protocol, the slides were immersed with preheated
citrate buffer (0.1 M Tri sodium citrate and 0.1 M citric acid
with a pH 6.0) in the pressure cooker on the hot plate. The
slides were exposed to steam inside pressure cooker until two
whistles are completed. Immediately, the pressure cooker was
subjected to cooling under running tap water. Endogenous
peroxidase activity was blocked for 10 min with 3% H2O2 in
H2O, and the slides were incubated with 1:75 rabbit polyclonal
affinity purified anti-KIF14 antibody in Tris buffer, pH 7.6
(BL358; Bethyl Laboratories, Genuine Chemical Corp, India)
and with 1:75 mouse monoclonal anti-E2F3 antibody in Tris
buffer, pH 7.6 (Upstate, Millipore, Billerica, MA), a kind gift
from  Rod  Bremner  (Toronto  Western  Research  Institute,
Toronto, Canada) separately. Immunostaining was performed
using  Dako  LSAB+system-horseradish  peroxidase
(Dakocytomation,  Glostrup,  Denmark).  The  reaction  was
revealed  by  3,  3′-diaminobenzidine  tetrahydrochloride
(Dakocytomation) and counterstained with hematoxylin. For
the  negative  control,  immunostaining  was  done  without
primary antibody.
Immunoanalysis:  Evaluation  of  immunostaining  in  tumor
cells was objectively performed by two investigators (J.M.
and K.M.) in 6 tumors from the cohort. Ten tumor fields were
randomly  scanned  for  protein  expression  under  40X,  and
percentage of positive tumor cells was noted for each field.
Finally, the average expression was calculated for the entire
slide from the 10 values. Depending on the percentage of
positive cells, 4 categories were established: 0, no positive
cells; 1+, positive cells in less than one-third; 2+, positive cells
in 33%–67% and 3+, positive cells in more than two-thirds of
total tumor cell population [10].
Statistical analysis: mRNA expression levels of KIF14 and
E2F3 in tumors were separately compared to those in RB cell
lines, fetal, age-matched and adult retinal controls using the
Mann–Whitney  U  test.  Associations  between  phenotypic
characteristics (median age at diagnosis and disease duration)
were also studied by Pearson’s coefficient of correlation. The
influence of familial tumors, laterality, differentiation, and
invasion on gene expression was assessed. The expression
levels  in  tumors  exposed  to  chemotherapy  were  analyzed
separately for significance against untreated tumor samples.
All analyses were performed with SPSS version 13.0 (SPSS
Inc., Chicago, IL) and p<0.05 was considered significant.
RESULTS
Quantification of KIF14 and E2F3 mRNA expression levels
in tumor and control samples: We quantified KIF14 and E2F3
mRNA  in  57  tumors  samples,  of  which  2  had  received
chemotherapy before enucleation (Figure 1). For controls,
KIF14 and E2F3 mRNA levels were determined in 4 fetal
(18–20-weeks gestation), 4 age-matched (13–18 months old),
4 adult retinas (21–60 years), and 3 RB cell lines (Y79, WERI,
and  RB381).  Levels  were  normalized  to  2  housekeeping
genes, GAPDH and HPRT. The average fold change between
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tumors with each control set was calculated, as well as that
between the untreated and treated tumor sets (Table 1). There
was  statistically  significant  overexpression  of  KIF14  and
E2F3 mRNA expression in tumors compared to fetal retinal,
age-matched and adult control retinas (p<0.0001). There was
a significant overexpression of E2F3 expression compared to
RB  cell  line  controls  (p=0.01).  The  chemotherapy-treated
subset showed a significant decrease in the expression of
KIF14 (p<0.01) and E2F3 (p<0.001) compared to untreated
tumors.
Phenotype correlation: We examined whether there was a
correlation  between  KIF14  and  E2F3  mRNA  expression
levels  in  the  55  untreated  tumors  and  various  tumor
phenotypes  (Table  2).  Samples  from  the  2  patients  who
received  chemotherapy  before  enucleation  were  excluded
from further analysis. There was a statistical increase in KIF14
expression with older age at presentation (p=0.01) and in
unilateral RB patients (p=0.04). No correlation was found
between  KIF14  mRNA  expression  and  differentiation,
familial tumors, invasion of the tumor into the choroid and
optic nerve, or the duration of the disease (defined as the
period between identification of symptoms to the time of
enucleation). Further, there was no correlation between the
mRNA expression of E2F3 and different tumor phenotypes
(Table 2).
Immunoreactivity of KIF14 in non-neoplastic retina and RB
tumor cells: No immunoreactivity for KIF14 or E2F3 was
noted in the control healthy retina (Figure 2A,D), whereas
KIF14 expression was localized to the nucleus and cytoplasm
in  tumor  cells  (Figure  2B,C),  and  E2F3  expression  was
localized to the nucleus (Figure 2E,F). All 6 tumors, which
were stained, showed heterogeneous expression of KIF14 (2+
staining) and E2F3 (3+ staining).
DISCUSSION
After knocking out the tumor suppressor RB1 gene in the
tumor-prone retinal cells, RB has to progress into full-fledged
Figure 1. Quantification of KIF14 and E2F3 mRNA expression levels in tumor and control samples calibrated to fetal control retina (F2).
There was statistically significant overexpression of KIF14 and E2F3 mRNA expression in tumors compared to fetal retinal, age-matched
and adult control retinas (p<0.0001). There was a significant overexpression of E2F3 expression compared to RB cell line controls (p=0.01).
The chemotherapy-treated subset (last two unshaded bars) showed a significant decrease in the expression of KIF14 (p<0.01) and E2F3
(p<0.001) compared to untreated tumors. Error bars represent standard error of the relative fold expression levels of KIF14 and E2F3.
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237malignancy. This is achieved by triggering oncogenes, which
can help in multiplication of the tumor cells. Different cancers
take  different  routes  for  progression  based  on  genetic
instability.  Comparative  genomic  hybridization  and
microarray-based  PCRs  have  been  narrowed  to  a  few
oncogenes, which probably helps RB to progress [11-14].
KIF14  and  E2F3  may represent  important pro-oncogenes,
TABLE 2. SIGNIFICANCE OF KIF14 AND E2F3 MRNA EXPRESSION LEVELS
COMPARED TO PHENOTYPE OF TUMORS.
Phenotype
Significant
variation in fold
KIF14 E2F3
Age at diagnosis (median 24
months)
0.01* 0.67
Duration (median 1.5 months) 0.34 0.55
Laterality 0.04* 0.28
Differentiation 0.31 0.91
Familial 0.63 0.19
Invasion 0.81 0.51
*There  was a statistical increase in KIF14 expression with
older age at diagnosis (p=0.01) and in unilateral RB patients
(p=0.04).
which have been seen to be deregulated in most RB tumors.
By real time PCR, we found an overexpression of these 2
oncogenes  in  all  tumors  studied  compared  to  fetal,  age-
matched and adult retinas. The sensitivity of real time PCR is
perhaps higher compared to the previously used techniques to
identify the amount and percentage of tumors, which showed
deregulation  in  the  genes  studied.  Nucleocytoplasmic
localization  of  KIF14  possibly   represent  its  cytoplasm
to  the  nucleus  mobilization  during  spindle  formation as
shown byprevious study [15]. This in addition to the nuclear
localization of E2F3 may represent the functional intactness
of both proteins in tumor cells. These 2 oncogenes act at
different points in the cell cycle to accomplish proliferation
after  deregulation  of  pRB.  E2F3  acts  as  a  transcriptional
activator of genes that are derepressed following transition
through the RB1-dependent G1/S-phase cell cycle checkpoint
[16], and play a role in DNA replication. KIF14 plays an
important  role  during  mitosis  [6,15],  and  overexpression
results in error-prone mitosis and tumor progression.
As seen with our earlier report [5], phenotype correlations
revealed  a  statistically  significant  increase  in  mRNA
expression of KIF14 in patients at older age at diagnosis.
There was a statistically significant increase in KIF14 mRNA
TABLE 1. KIF14 AND E2F3 MRNA EXPRESSION IN TUMORS COMPARED TO CONTROL SAMPLES.
Control
Gene                 Average
expression          fold change
a
Increased                         Decreased
  # of             Fold
tumors           upa
  # of                Fold
tumors            downa
Fetal retina compared
to chemotherapy
untreated tumors
KIF14 7.0 <0.0001* 57 1.1–29.1 0 -
E2F3 20.4 57             3–110.7
Age matched retina
compared to
chemotherapy
untreated tumors
KIF14 239.7 57             40–1000 0 -
E2F3 50.3 57            1.1–280.5             0
Adult retina compared
to chemotherapy
untreated tumors
KIF14b - - - - -
E2F3 17.8 56              2.6–96.4              1
Cell lines compared to
chemotherapy
untreated tumors
KIF14 2.5 0.13 44 1.1–10.6 13 1–2.3
E2F3 5.0 0.01* 54             1.1–27.3               3 1–1.3
Tumor after
chemotherapy
compared to
chemotherapy
untreated tumors
KIF14 34.9 0.01* 53 1.3–23.7               2 1.1–3.5
E2F3 5.8 0.001*                  55            5.8–145.8 0
Statistical significance of KIF14   and E2F3  mRNA expression in tumors compared to control samples. aFold change is expressed
relative to the median of the control samples. bShows infinity value against adult retina controls. *Statistically significant.
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p value
0
1.1
-expression  with  unilateral  RB  compared  to  bilateral  RB
(p=0.04), which was not reported in our earlier study. As the
median age at diagnosis of unilateral RB is late compared to
bilateral RB, this correlates with a significant increase in the
levels  of  KIF14  mRNA  expression  in  older  age  at
presentation. Probably unilateral late onset tumors need more
genetic instability for tumor progression, as retinal cells are
in the final stage of terminal differentiation. E2F3 mRNA
expression levels did not show statistical significance with
different phenotype variables. As KIF14 and E2F3 genes have
a role in cell proliferation, and the severity of RB is related to
the rate of proliferation of the tumor, even with known bias in
the patient’s history, duration of the disease was calculated for
individual patients and correlated with the relative KIF14 and
E2F3 mRNA expressions. No significant variability in KIF14
and  E2F3  mRNA  expression  was  noted  with  increase  or
decrease in disease duration.
The highly statistically significant decrease in the levels
of  KIF14  mRNA  expression  (p<0.01)  and  E2F3  mRNA
expression (p<0.001) in chemotherapy-treated cases shows
the effect of chemotherapy on proliferative tumor cells. This
needs further validation in more numbers of chemotherapy
treated  tumor  samples.  In  addition  to  the  aforedescribed
finding, the statistical increase in the mRNA expression of
E2F3 in fresh tumors compared to RB cell lines (p=0.01)
discourages the use of RB cell lines to evaluate this gene for
further studies.
This is the first report on the levels of two important
candidate genes (KIF14 and E2F3) for proliferation of RB
tumor simultaneously done in a larger cohort with phenotype
association.
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